Fernández-de-Misa, RHernández-Machín, BServitje, OValentí-Medina, FMaroñas-Jiménez, LOrtiz-Romero, P LSánchez Schmidt, JPujol, R MGallardo, FPau-Charles, IGarcía Muret, M PPérez Gala, SRomán, CCañueto, JBlanch Rius, LIzu, ROrtiz-Brugués, AMartí, R MBlanes, MMorillo, MSánchez, PPeñate, YBastida, JPérez Gil, ALopez-Lerma, IMuniesa, CEstrach, T2023-01-252023-01-252017-10-10http://hdl.handle.net/10668/11661Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. To assess the daily clinical practice approach to LyP and the response to first-line treatments. This was a retrospective study enrolling 252 patients with LyP. Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P  0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P  Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse.enCC0 1.0 Universalhttp://creativecommons.org/publicdomain/zero/1.0/Administration, TopicalAdolescentAdultAgedAged, 80 and overAntimetabolites, AntineoplasticChildChild, PreschoolDisease-Free SurvivalFemaleHumansInfantLymphomatoid PapulosisMaleMethotrexateMiddle AgedMycosis FungoidesNeoplasms, Multiple PrimaryPhototherapyReceptors, Antigen, T-CellRetrospective StudiesSkin NeoplasmsSteroidsYoung Adultresearch article28994134open access10.1111/ced.132561365-2230http://diposit.ub.edu/dspace/bitstream/2445/120231/1/674076.pdf